Project Grant R61MH136135
- This $514,178 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to investigate the relationship between brain circuit function and negative valence system behavioral abnormalities in treatment-resistant depression (TRD). The 5-year study, conducted by the Laureate Institute for Brain Research, Inc., will use low-intensity focused ultrasound (LIFU) neuromodulation to determine how connectivity between the...
- This Project Grant award of $777,016.00 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research on the synaptic mechanisms of continuous theta burst stimulation (CTBS) in the treatment of depression. The project aims to investigate whether CTBS reduces excitation via N-methyl-D-aspartate receptor (NMDAR)-dependent long-term depression (LTD) and/or enhances inhibition via gamma-aminobutyric acid receptors (GABARs) in...
- The National Institute of Mental Health (NIMH) awarded a $156,500 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to Emory University to identify patients with true treatment failure for major depressive disorder (MDD) who may benefit from earlier referral to alternative treatments like transcranial magnetic stimulation, ketamine, and vagus nerve stimulation. The project aims to use trajectory classification methods to empirically separate partial response from true...
- This federal Project Grant award, titled "MAINTENANCE RTMS FOR DEPRESSION (MAITR-DE)", is funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242). The $968,769 award will support a multi-site study to investigate the efficacy of maintenance repetitive transcranial magnetic stimulation (rTMS) in sustaining treatment response for individuals with treatment-resistant depression. The study will be conducted by the University of...
- The National Institute of Mental Health (NIMH) awarded Ampa Inc., a $1,199,261 project grant under the Mental Health Research Grants program (CFDA 93.242) to develop a next-generation Transcranial Magnetic Stimulation (TMS) system that improves upon current FDA-approved TMS treatments for depression. The key innovations of this system include: (1) precision TMS targeting based on neurocardiac response signals instead of functional MRI, (2) a camera and scalp cap system for neuronavigation rather...
- This Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), will support a study to evaluate the use of repetitive transcranial magnetic stimulation (rTMS) to treat depression in individuals with schizophrenia spectrum disorders. The $1,125,194 award, with a project period from August 15, 2025 to August 14, 2027, will fund a two-phase study conducted by the University of Texas Health Science Center at Houston...
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $406,080 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to develop and evaluate a daily, digital mindfulness-based intervention for reducing depressive symptoms in post-treatment cancer patients. The key products and services to be delivered under this 5-year project include: 1) developing the "MINDSET" daily...
- This $1,651,499 Project Grant awarded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will be used to assess the proof-of-mechanism for the efficacy of a novel non-invasive brain stimulation method called Kilohertz Transcranial Magnetic Perturbation (KTMP) in improving anhedonia, a core symptom of major depressive disorder (MDD). The 3-year award to Magnetic Tides, Inc., a for-profit company in El Cerrito, CA, will focus on...
- The National Institute of Mental Health (NIMH) awarded a $1,561,396 Project Grant under the Mental Health Research Grants program (CFDA 93.242) to the University of Wisconsin-Madison. The grant will fund a 4-year study to optimize the integration of human and digital support components in the Healthy Minds Program, a widely-used meditation app, to enhance its effectiveness in treating depression and anxiety. The study will use a hybrid factorial and micro-randomized trial design to evaluate...
- This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 - Mental Health Research Grants provides $638,872 to The Feinstein Institutes for Medical Research to conduct research on "Elucidating Reward Network Modulation in Medial Forebrain Bundle Deep Brain Stimulation for Treatment Resistant Depression". The goal is to use brain imaging to understand how deep brain stimulation of the medial forebrain bundle impacts the brain's reward processing...
MINDFULNESS ENGAGED NEUROSTIMULATION FOR DEPRESSION (MEND) - PROJECT SUMMARY DEPRESSION AFFECTS 1-IN-5 INDIVIDUALS IN THE UNITED STATES AND HAS A TREMENDOUS COST BURDEN FOR OUR ECONOMY AT $210 BILLION PER YEAR. DEPRESSION IS HARD TO TREAT GIVEN THAT IT IS A HETEROGENEOUS ILLNESS ASSOCIATED WITH AFFECTIVE, COGNITIVE AND BEHAVIORAL DYSREGULATION. AROUND 33% OF DEPRESSED INDIVIDUALS WILL NOT RESPOND TO THE FIRST TWO TREATMENTS OFFERED. IN THIS CONTEXT, THERE IS INCREASING EVIDENCE THAT COGNITIVE FUNCTIONING IN MAJOR DEPRESSION MAY BE AN INDEPENDENT FACTOR PREDICTING TREATMENT RESPONSE, QUALITY OF LIFE, DISABILITY AND SUICIDE, AND COGNITIVE CONTROL (CC) DEFICITS MAY PERSIST EVEN WHEN OTHER DEPRESSION SYMPTOMS REMIT. FOR INSTANCE, FDA-APPROVED THERAPIES FOR TREATMENT-RESISTANT-DEPRESSION (TRD) SUCH AS REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION (RTMS) TARGET THE DORSOLATERAL PREFRONTAL CORTEX (DLPFC) BRAIN REGION THAT IS CRUCIAL FOR CC. BUT RTMS STUDIES SHOW REMISSION RATES OF ONLY ~30%, AND THERE IS NO EVIDENCE THAT RTMS FOR DEPRESSION IMPROVES CC. THIS SUGGESTS THAT FOR INDIVIDUALS WITH TRD, SYNERGISTICALLY TARGETING CC ALONGSIDE TREATMENTS LIKE RTMS MAY AUGMENT DEPRESSION TREATMENT RESPONSE, IMPROVE QUALITY OF LIFE AND POTENTIALLY REDUCE MORBIDITY AND MORTALITY. WHILE MULTIPLE OPTIONS MAY EXIST FOR TARGETING CC, BASED ON OUR PRELIMINARY EVIDENCE, HERE WE PROPOSE TO USE A DIGITAL BREATH-FOCUSED ATTENTION TRAINING PARADIGM PAIRED WITH DLPFC RTMS. WE HYPOTHESIZE THAT THIS MULTIMODAL NEUROTHERAPY WILL SIGNIFICANTLY IMPROVE CC, AND RESULT IN BETTER ANTIDEPRESSANT TREATMENT RESPONSE THAN OBSERVED WITH EXTANT RTMS TREATMENT, PARTICULARLY BY ENGAGING THE NEURAL TARGET OF DEFAULT MODE NETWORK (DMN) ACTIVITY SUPPRESSION. OUR RATIONALE FOR PAIRING DIGITAL BREATH ATTENTION TRAINING WITH RTMS IS THAT MINDFULNESS-BASED INTERVENTIONS THAT HAVE A CORE FOUNDATION IN TRAINING ATTENTION TO INTERNAL SENSATIONS SUCH AS BREATHING, CAN IMPROVE CC AND ALSO AMELIORATE RUMINATIVE SYMPTOMS OF DEPRESSION. DIGITAL TRAINING, COMPARED TO THERAPIST DELIVERED, ALLOWS FOR GREATER SCALABILITY, IMMEDIATE FEEDBACK ON PERFORMANCE AND APPLICATION OF ALGORITHMIC CLOSED-LOOP TRAINING METHODS TAILORED TO EACH SUBJECT'S PERFORMANCE. FROM A COGNITIVE NEUROSCIENCE VIEWPOINT, THE CC DEFICITS THAT OCCUR IN DEPRESSION ARE LINKED WITH IMPAIRED TOP-DOWN CONTROL OF DMN ACTIVITY. BOTH DLPFC RTMS AND MINDFULNESS TRAINING ARE HYPOTHESIZED TO WORK, IN PART, BY ENHANCING EFFICACY OF TOP-DOWN/PREFRONTAL SUPPRESSION OF DMN, SUGGESTING POTENTIAL SYNERGY OF THESE DISTINCT APPROACHES. WE THEREFORE HYPOTHESIZE THAT OUR MULTIMODAL NEUROTHERAPEUTIC STRATEGY OF PAIRING A DIGITAL BREATH ATTENTION TRAINING THAT IS AKIN TO MINDFULNESS TRAINING, WITH RTMS WILL RESULT IN IMPROVED CC, AS WELL AS ENHANCED ANTIDEPRESSANT EFFECTS. THE R61 PHASE OF THE PROJECT WILL FOCUS ON DOSE RESPONSE OF THE MULTIMODAL THERAPY FOR NEURAL TARGET ENGAGEMENT, I.E. DMN ACTIVITY SUPPRESSION, WHILE THE R33 PHASE WILL REPLICATE NEURAL TARGET ENGAGEMENT AND ALSO AIM TO SHOW IMPROVEMENT IN CC AND GREATER DEPRESSIVE SYMPTOM RESPONSE TO TREATMENT IN A RANDOMIZED CONTROLLED TRIAL.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $708.1k | 5/2/25 | ||
| Not listed | $93.6k | 6/6/24 | ||
| Not listed | $93.6k | 6/6/24 | ||
| Not listed | $795.2k | 4/25/24 | ||
| Not listed | $795.2k | 4/25/24 |